Live Breaking News & Updates on Oric Pharmaceuticals Inc|Page 9

Stay updated with breaking news from Oric pharmaceuticals inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Recent Analysts' Ratings Updates for ORIC Pharmaceuticals (ORIC)

Several analysts have recently updated their ratings and price targets for ORIC Pharmaceuticals (NASDAQ: ORIC): 4/4/2022 – ORIC Pharmaceuticals was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $10.00 price target on the stock, up previously from $7.00. 3/30/2022 – ORIC Pharmaceuticals was downgraded by […] ....

United States , San Francisco , Dominic Piscitelli , Jacob Chacko , Securities Exchange Commission , Life Insurance Co , Zacks Investment Research , Deutsche Bank , Oppenheimer Holdings Inc , American International Group Inc , Pharmaceuticals Inc , Citigroup Inc , Royal Bank , Us Bancorp , Oppenheimer Holdings , Get Rating , Exchange Commission , International Group , Oric Pharmaceuticals Inc , Nasdaq Oric ,

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Buys 60,000 Shares

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Rating) CFO Dominic Piscitelli bought 60,000 shares of the firm’s stock in a transaction on Thursday, March 31st. The shares were acquired at an average cost of $5.36 per share, with a total value of $321,600.00. The acquisition was disclosed in a filing with the SEC, which can be […] ....

Dominic Piscitelli , Thomson Reuter , Arrowmark Colorado Holdings , Zacks Investment Research , Blackrock Inc , Pharmaceuticals Company Profile Get Rating , Oric Pharmaceuticals Inc , Victory Capital Management Inc , Pharmaceuticals Inc , Get Rating , Capital Management , Street Corp , Mark Colorado Holdings , Investment Research , Company Profile , Oric Pharmaceuticals , Nasdaq Oric , Insider Trading , Nsider Trades ,

Recent Investment Analysts' Ratings Changes for ORIC Pharmaceuticals (ORIC)

A number of research firms have changed their ratings and price targets for ORIC Pharmaceuticals (NASDAQ: ORIC): 3/25/2022 – ORIC Pharmaceuticals was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. 3/25/2022 – ORIC Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” […] ....

United States , San Francisco , Thomson Reuter , Jacob Chacko , Securities Exchange Commission , Life Insurance Co , Zacks Investment Research , Ensign Peak Advisors Inc , Oppenheimer Holdings Inc , Advisors Inc , Pharmaceuticals Inc , Citigroup Inc , Us Bancorp , Royal Bank , Oppenheimer Holdings , Get Rating , Exchange Commission , Oric Pharmaceuticals Inc , Nasdaq Oric ,

ORIC Pharmaceuticals, Inc. to Post Q1 2022 Earnings of ($0.58) Per Share, Jefferies Financial Group Forecasts (NASDAQ:ORIC)

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2022 earnings per share estimates for ORIC Pharmaceuticals in a research note issued on Tuesday, March 22nd. Jefferies Financial Group analyst M. Raycroft expects that the company will post earnings of ($0.58) per share for the quarter. Jefferies […] ....

Life Insurance Co , Ensign Peak Advisors Inc , Pharmaceuticals Company Profile Get Rating , Jefferies Financial Group , Advisors Inc , Oric Pharmaceuticals Inc , Pharmaceuticals Inc , Us Bancorp , Royal Bank , Get Rating , Financial Group , Company Profile , Oric Pharmaceuticals , Nasdaq Oric , Earnings Estimates , Jefferies Financial Group Inc ,